# Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa

> **NCT01975441** · PHASE2 · COMPLETED · sponsor: **University Hospitals Cleveland Medical Center** · enrollment: 182 (actual)

## Conditions studied

- Lymphatic Filariasis

## Interventions

- **DRUG:** Diethylcarbamazine
- **DRUG:** Albendazole
- **DRUG:** Ivermectin

## Key facts

- **NCT ID:** NCT01975441
- **Lead sponsor:** University Hospitals Cleveland Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2017-12
- **Final completion:** 2018-06
- **Target enrollment:** 182 (ACTUAL)
- **Last updated:** 2018-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01975441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01975441, "Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01975441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*